Since the publication of The Hallmarks of Aging in 2013, aging research has exploded. The field now has more than 300,000 articles on the biological signals of the effect of time on the body. What would Marty McFly, the legendary character from the Back to the Future saga who traveled with his DeLorean time machine from the ‘80s to the ‘50s, think if he visited 2024 and saw laboratories experimenting with techniques to turn back the biological clocks of cells or increase the lifespan of rejuvenated mice? Read More

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide and is characterized by an abnormal inflammatory reaction of the lungs to inhaled particles, such as cigarette smoke. On the other hand, the transcription factor interferon responsive factors (IRFs) are key elements in the production of type I and III interferons. A group of researchers in Italy looked into the relationship between interferon regulatory factor 3 (IRF3) and COPD outcomes. Read More

Bayer AG and Nextrna Therapeutics Inc. have entered into a collaboration and license agreement to develop small-molecule therapeutics targeting long noncoding RNAs (lncRNAs) in oncology. Under the agreement, Bayer gains access to Nextrna’s differentiated approach to inhibit the function of lncRNAs by disrupting the interaction between lncRNAs and RNA-binding proteins (RBPs) with small molecules. Read More

Eydisbio Inc. has been awarded a $2.6 million phase II Small Business Innovation Research (SBIR) grant from the National Institute of Health’s (NIH) National Heart, Lung, and Blood Institute (NHLBI) to support its ongoing research into the efficacy of TAK1 inhibition in animal models of systemic sclerosis. Read More

Pulmonary arterial hypertension (PAH) is a progressive disorder where high pulmonary artery pressure and vascular resistance lead to progressive dyspnea, and right ventricular hypertrophy (RVH). Read More

Mestag Therapeutics Ltd. has been awarded a £1.5 million ($1.9 million) grant from Innovate UK’s Cancer Therapeutics program to accelerate the development of MST-0300. Read More

Hemoshear Therapeutics Inc. has identified new 3-((1,1-dioxido-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)-2-fluoroacrylic acid derivatives acting as sodium-bile acid cotransporter (SLC10A1; NTCP) inhibitors. Read More

Suven Life Sciences Ltd. has received IND approval from the FDA allowing it to initiate a first-in-human phase I study of SUVN-I6107, a muscarinic M1 receptor positive allosteric modulator (PAM) as a potential new treatment to address the dementia market. Read More

Synnovation Therapeutics Inc. has patented phosphatidylinositol 3-kinase α (PI3K-α) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum and CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities). Read More

Bristol Myers Squibb Co. has prepared and tested new Substituted benzimidazole compounds acting as Toll-like receptor 9 (TLR9) antagonists. They are reported to be useful for the treatment of fibrosis, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, cancer, primary sclerosing cholangitis, idiopathic pulmonary fibrosis, inflammatory and autoimmune diseases. Read More

Researchers from Shenzhen University and affiliated organizations detailed the preclinical characterization of a synergistic intravesical instillation of fenbendazole (FBZ) and CRISPR-Cas13a-based nanoplatform as a new strategy for the treatment of bladder cancer. Read More

An Uppthera Inc. patent describes new proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently linked to a serine/threonine-protein kinase PLK1 (STPK13)-targeting moiety; they are reported to be useful for the treatment of cancer and neurological disorders. Read More

Medulloblastoma is one of the most common malignant pediatric brain tumors that accounts for approximately 70% of all embryonal CNS tumors from 0 to 19 years. Read More

Antibodies targeting cytotoxic T-lymphocyte protein 4 (CLTA-4) have faced challenges due to frequent adverse events and limited efficacy, thus pushing the search for next-generation anti-CTLA-4 antibodies that balance T regulatory cell (Treg) depletion with CD8 T-cell activation for cancer immunotherapy. Read More

Korean Research Institute of Bioscience and Biotechnology and Korea Research Institute of Chemical Technology have jointly developed molecular glue degraders acting as zinc finger protein Helios (IKZF2) degradation inducers. They are described as potentially useful for the treatment of cancer. Read More